주요서비스 바로가기
본문 바로가기
매체정보 바로가기
로그인 바로가기
기사검색 바로가기
전체서비스 바로가기
Updated : Thursday, March 28, 2024, 21:15
Home
Login
Sign in
한국어
National
Foreign Affairs
Central & Regional Affairs
Social Issues
Economics
Macro-Economics
Trade
Foreign Exchanges
Industries
ICT
Automobiles
Heavy & Chemical
Defence
Entertainment
Energy
Construction
Healthcare & Bio
Consumer
Services
Stock Market
Company & Stock Tracking
Market Trend & Outlook
Finance
Capital Market
Crypto
Banking
Insurances
Startups
Science/Tech
Science
New Tech
Blockchain
ESG
Environment
Social
Governance
Event
Exhibitions
Conferences
People
K-Culture
Cinema/Drama
K-pop
Food
Lifestyle
Arts/Culture
Opinion
Editorials
Contributions
Who's Who
기사검색
검색
All articles
List
Subject Type
Summary Type
Photo Type
[Yuhan] First data update since last October
이미지기사
Company & Stock Tracking
Pyeongkuk Park
03.26 08:34
[Yuhan Corp] Internal sales estimate for amivantamab+lazertinib combo twice as high as consensus
이미지기사
Company & Stock Tracking
Pyeongkuk Park
2023.12.07 15:39
[Yuhan Corp] MARIPOSA proves feasibility of first-line treatment
이미지기사
Company & Stock Tracking
Pyeongkuk Park
2023.10.25 09:49
Spot Comment/Yuhan - Five things to watch for after phase III MARIPOSA success
이미지기사
Company & Stock Tracking
Pyeongkuk Park
2023.10.04 22:13
The next Yuhan
이미지기사
Company & Stock Tracking
Seungyeon Han
2023.09.27 15:09
Earnings beat consensus, but this is just the start
이미지기사
Finance
Pyeongkuk Park
2023.07.31 18:33
Value of first-line NSCLC therapy far higher than expected
이미지기사
Finance
Pyeongkuk Park
2023.07.04 15:07
Expect earnings improvement and new drug momentum
이미지기사
Finance
Pyeongkuk Park
2023.04.10 17:51
Yuhan: Laser301 Data Are Promising
이미지기사
Finance
Park Pyeong-kuk
2022.12.05 15:09
Yuhan: R&D Momentum Expected through 2023
이미지기사
Finance
Jang Se-hun & Lee Dong-gun
2022.10.17 10:39
Yuhan: Expectations Towards Lazertinibon Rising Following WCLC Abstract Releases
이미지기사
Finance
Park Pyeong-kuk
2022.07.14 15:12
Bio Industry: Pay Attention to Nascent Subsectors
Finance
Park Pyeong-kuk
2022.06.16 09:48
Bio Industry: 2022 ASCO: Start Identifying Investment Opportunities via Selective Approach in 2H22
Finance
Park Pyeong-kuk
2022.05.30 13:58
Yuhan Corp.: 1Q22 Review: Plenty More Than Lazertinib
이미지기사
Finance
Kim Tae-hee
2022.05.02 13:32
Yuhan Corp.: Focus More on R&D Than Earnings Momentum
이미지기사
Finance
Kim Tae-hee
2022.02.28 16:56
Yuhan: Domestic Sales and Licensing Fees Disappoint
이미지기사
Finance
Park Pyeong-kuk
2022.02.17 11:28
2022 Outlook: Pharmaceutical/Bio: Will Pharma/bio Stocks Return to Their Glory?
Finance
Park Pyeong-kuk
2021.11.22 15:41
Yuhan: Visualization of Lazertinib's Global Market Launch
이미지기사
Finance
Park Pyeong-kuk
2021.10.08 14:13
Abion: In Possession of Powerful c-MET Technology
이미지기사
Finance
Park Pyeong-kuk
2021.09.15 09:37
Yuhan: Main Business Recovering, Starting with Domestic Leclaza
이미지기사
Finance
Park Pyeong-kuk
2021.07.30 14:05
처음
1
끝
위로
모바일버전
All articles
National
전체
Foreign Affairs
Central & Regional Affairs
Social Issues
Economics
전체
Macro-Economics
Trade
Foreign Exchanges
Industries
전체
ICT
Automobiles
Heavy & Chemical
Defence
Entertainment
Energy
Construction
Healthcare & Bio
Consumer
Services
Stock Market
전체
Company & Stock Tracking
Market Trend & Outlook
Finance
전체
Capital Market
Crypto
Banking
Insurances
Startups
Science/Tech
전체
Science
New Tech
Blockchain
ESG
전체
Environment
Social
Governance
Event
전체
Exhibitions
Conferences
People
K-Culture
전체
Cinema/Drama
K-pop
Food
Lifestyle
Arts/Culture
Opinion
전체
Editorials
Contributions
Who's Who
전체메뉴닫기